Phase III trial of a 3-weekly versus 5-weekly schedule of S-1 plus cisplatin (SP) combination chemotherapy for first-line treatment of advanced gastric cancer (AGC): SOS study.
Min-Hee Ryu
Honoraria - Jeil Pharmaceutical Co
Research Funding - Jeil Pharmaceutical Co
Eishi Baba
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Kyung Hee Lee
No relevant relationships to disclose
Narikazu Boku
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Young Iee Park
No relevant relationships to disclose
Ichinosuke Hyodo
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Byung-Ho Nam
No relevant relationships to disclose
Taito Esaki
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Baek-Yeol Ryoo
No relevant relationships to disclose
Eun-Kee Song
No relevant relationships to disclose
Sanghee Cho
No relevant relationships to disclose
Sung Sook Lee
No relevant relationships to disclose
Won Ki Kang
No relevant relationships to disclose
Sung Hyun Yang
No relevant relationships to disclose
Dae Young Zang
No relevant relationships to disclose
Dong Bok Shin
No relevant relationships to disclose
Sook Ryun Park
No relevant relationships to disclose
Katsunori Shinozaki
Honoraria - Taiho Pharmaceutical
Toshimi Takano
No relevant relationships to disclose
Yoon-Koo Kang
Honoraria - Novartis; Roche; Sanofi ; Taiho Pharmaceutical
Research Funding - Jeil Pharmaceutical Co; Novartis; Roche; Sanofi